Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
license save search
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% -21.92% 420K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Motorsport Games and British Touring Car Championship Announce Settlement and New Licensing Agreement
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
MSGM | $2.63 5.62% 5.32% 14K
|
| Email alert
Add to watchlist
games agreement
Adeia Enters into IP License Agreement with Magenta Telekom
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ADEA | $9.95 2.26% 2.21% 480K
|
Manufacturing
|
| O: -1.59%
H: 0.0%
C: 0.0%
license agreement
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 2.68%
H: 3.48%
C: -11.3%
treatment biopharma royalties global for agreement
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: -0.82%
H: 0.0%
C: 0.0%
disorders treatment for agreement
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Music Licensing Inc. (OTC: SONG) and Jake P. Noch Family Office, LLC. initiated communication with the Government of Jamaica regarding Investment Treaty Claims on February 13, 2024.
Published: 2024-04-10 (Crawled : 13:00) - globenewswire.com
SONG | $0.0002 0.0% 21M
|
n/a
|
| O: 100.0%
H: 0.0%
C: -50.0%
communication family initiated
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 5.74%
H: 1.55%
C: -11.63%
biopharma royalties global for
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 1.87%
H: 4.59%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
Northann Corp Announces Cross-Licensing Agreement with I4F for Digital Printing Technology
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
NCL | $0.495 -0.2% 44K
|
|
| O: 4.08%
H: 2.94%
C: 2.94%
for technology agreement
Anfield Energy Achieves Significant Milestone to Recommence Uranium Production at Shootaring as the Company Submits its Mill Reactivation Plan to the State of Utah, Which Includes a Tripling of Licensed Production Capacity
Published: 2024-04-09 (Crawled : 11:00) - globenewswire.com
ANLDF | $0.0634 -2.5% 170K
|
Non-Energy Minerals
|
| O: 3.0%
H: 2.47%
C: 2.47%
energy company state capacity uranium milestone
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Published: 2024-04-04 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
candidate biosimilar global for teva agreement
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.18%
H: 0.34%
C: -0.22%
breast her2 license cancer application negative
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Published: 2024-04-02 (Crawled : 05:00) - globenewswire.com
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 2.03%
H: 6.14%
C: -8.12%
tumors biopharma global agreement
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement
Eco Wave Power Announces 1,076% Revenue Increase, Investment Agreement with Major Energy Company for its LA Project, and Final License for the Construction of its First Commercial Project in Portugal
Published: 2024-04-01 (Crawled : 13:30) - prnewswire.com
WAVE | $4.05 11.57% 10.37% 290K
|
|
| O: 13.46%
H: 11.02%
C: 0.85%
CVX | $160.0 1.54% -0.02% 7.7M
|
Energy Minerals
|
| O: 0.34%
H: 0.83%
C: 0.51%
first energy company license construction revenue commercial agreement
Wearable Devices Signs Reseller Agreement to Scale its Licensing Program Reach to Enterprises in South Korea and China
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
WLDS | $0.49 -5.77% -6.12% 200K
|
|
| O: -1.96%
H: 1.44%
C: -5.45%
reach program agreement china
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement china
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.